Last reviewed · How we verify
Sturlimogene Erparepvec
At a glance
| Generic name | Sturlimogene Erparepvec |
|---|---|
| Also known as | Oncolytic Herpes Simplex Virus-1 Expressing Anti-CTLA-4 Antibody-like Molecule and GM-CSF RP2, Oncolytic Herpes Simplex Virus-1 Expressing Anti-CTLA-4 Antibody-like Molecule/GM-CSF RP2, Oncolytic HSV-1 Expressing Anti-CTLA-4 Antibody-like Molecule and GM-CSF RP2, Oncolytic HSV-1 Expressing Anti-CTLA-4 Antibody-like Molecule/GM-CSF RP2, Oncolytic Virus RP2 |
| Sponsor | City of Hope Medical Center |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |